Lupin Launches Generic Fosaprepitant Injection In US
Pharma major Lupin on Monday said it has launched generic Fosaprepitant injection, used to prevent nausea and vomiting associated with cancer chemotherapy in adults, in the American market. The company has launched Fosaprepitant for injection, 150 mg single-dose vial, having received an approval earlier for it from the United States Food and Drug Administration (USFDA), Lupin said in a filing to the BSE.The product is a generic version of Merck Sharp & Dohme Corp's Emend for injection in the same strength, it added.According to IQVIA MAT July 2020 data, Fosaprepitant for injection, 150 mg single-dose vial, had annual sales of approximately USD 136 million (about Rs 1,000 crore) in the US, Lupin said.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
